The board of directors of Kintor Pharmaceutical Limited announced that the phase Ib/III clinical trial of KX-826, a potential first-in-class drug developed by the Group, in combination with minoxidil for the treatment of androgenetic alopecia ("AGA") of male adults (the "Phase Ib/III Clinical Trial") was cleared by the National Medical Products Administration (the "NMPA"). This trial is aimed to evaluate the efficacy and safety of KX-826 in combination with minoxidIL for the treatment of male adults with AGA in China. KX-826 is one of the core drugs of the Group.

Since its development, it has completed multiple clinical trials for the treatment of male and female AGA in China and the United States, which has demonstrated excellent safety profile and efficacy trend. Minoxidil, approved by the US Food and Drug Administration (the "FDA") in 1988, is one of the mainstream approved drugs for the treatment of AGA. The Group believes that through the development of combination therapy, the value of KX-826 for AGA will be further discovered.

In the meanwhile, the Group is also conducting or planning multiple clinical trials of KX-826 For the treatment of AGA and acne, continuing to explore the value of KX- 826 in the field of dermatology.